AstraZeneca Pharma India

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

9 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Healthcare, Pharma & Life Sciences Just now (07:19 PM IST)

Medico Remedies Among Five Healthcare Stocks to Hit 52-Week Lows as Sensex Slips 242 Points

Indian healthcare counters came under renewed pressure on Thursday, with five BSE Healthcare Index stocks touching fresh 52-week lows as the Sensex fell 242 points to 72,529. Medico Remedies, Pfizer, AstraZeneca Pharma India, Sanofi Consumer Healthcare India and Eris Lifesciences all marked their weakest levels in a year, underscoring the depth of the sector’s recent correction. Several of these names have now shed as much as 48% in a month, reflecting sustained selling in defensive pockets of the market.

By RDU Global Wire4 min read

Global Markets & Equities07 Oct 2026, 08:14 AM IST

AstraZeneca bets on Kendall Square R&D hub to power next phase of growth

AstraZeneca has opened a major research and development center in Cambridge’s Kendall Square, a move that underscores the drugmaker’s determination to deepen its U.S. innovation footprint and sustain growth well beyond the current decade. The company says the site, backed by more than $1 billion in investment in Massachusetts, is designed to accelerate discovery with advanced automation, robotics and a denser concentration of scientific talent.

5 min readRead →

Global Health & Biotech06 Oct 2026, 08:29 AM IST

AstraZeneca CEO Says Summit Drug Could Anchor Next Wave of Cancer Combinations After $2 Billion Bet

AstraZeneca Chief Executive Pascal Soriot said Summit Therapeutics’ cancer drug could become a foundation for the next generation of combination therapies, underscoring why the Anglo-Swedish drugmaker has committed about $2 billion to the biotech. The comments come as AstraZeneca and Daiichi Sankyo move to test Summit’s ivonescimab alongside Datroway, a sign that large pharmaceutical groups are racing to secure the most promising assets in oncology.

5 min readRead →

Global Markets & Equities05 Nov 2026, 08:00 PM IST

Boehringer Returns to Sino Biopharma in $7.4 Billion Cancer Pact

Boehringer Ingelheim has struck a new oncology partnership with Sino Biopharma, reviving a relationship that now carries a headline value of up to $7.4 billion. The deal centers on preclinical bispecific T-cell engagers and antibody-drug conjugates, underscoring how large drugmakers are still willing to pay for early-stage cancer assets with long-dated optionality. The agreement adds another major cross-border licensing transaction to a market already defined by capital discipline, pipeline replenishment and intense competition for differentiated oncology platforms. For investors, the structure signals both the scale of demand for next-generation cancer modalities and the long development runway that will determine how much of the deal value ultimately becomes payable.

6 min readRead →

Markets, IPOs & Wealth05 Nov 2026, 02:00 PM IST

Sun Pharma Shares in Focus as Traders Track Current Price Action Amid Broader Market Caution

Sun Pharmaceutical Industries Ltd. is drawing close market attention as investors monitor its live share price against a backdrop of cautious trading across Indian equities. The stock’s movement is being read not just as a company-specific signal, but also as a gauge of sentiment toward large-cap healthcare names in a volatile macro environment. With fiscal and macroeconomic cues still shaping risk appetite, Sun Pharma’s current trading pattern is likely to remain under scrutiny from institutional and retail investors alike. Market participants are watching for whether the counter can sustain momentum, consolidate, or face pressure from broader sector rotation.

5 min readRead →

Healthcare, Pharma & Life Sciences01 Nov 2026, 02:00 PM IST

Sun Pharma Q2 Profit Falls 36% as Litigation and Deal Costs Weigh on Earnings

Sun Pharmaceutical Industries reported a 36% drop in second-quarter net profit to Rs 1,989 crore, as exceptional litigation and acquisition-related expenses sharply reduced earnings. Revenue rose 11.8% on the back of strong domestic and emerging-market demand, but weakness in the US formulations business tempered the overall performance.

4 min readRead →

Global Markets & Equities17 Oct 2026, 08:00 AM IST

Epic Unites Amazon Pharmacy, LillyDirect and Mark Cuban in Drug Price Tool Push

Epic Systems is launching a prescription drug pricing tool with Amazon Pharmacy, LillyDirect and Mark Cuban’s Cost Plus Drugs, aiming to give patients cash-price comparisons before they leave the doctor’s office. The move could sharpen competition in retail pharmacy and drug distribution while advancing a broader push for price transparency in U.S. healthcare.

5 min readRead →

Healthcare, Pharma & Life Sciences10 Oct 2026, 11:02 AM IST

GST Council Allows Pharma Firms to Claim Input Tax Credit on Free Samples, Expired Goods from FY28

The GST Council has approved a significant relief for pharmaceutical companies, allowing them to claim input tax credit on free samples and on goods destroyed after expiry, with the changes set to take effect from the next fiscal year. The move is expected to ease a long-standing tax burden on drug makers and align GST treatment more closely with the practical realities of pharmaceutical distribution and inventory management.

6 min readRead →

Healthcare, Pharma & Life Sciences10 Oct 2026, 04:12 AM IST

GST Council Allows Pharma Firms to Claim Input Tax Credit on Free Samples, Expired Goods from FY28

The GST Council has approved a significant relief for pharmaceutical companies, allowing them to claim input tax credit on free samples and goods destroyed after expiry, effective from the next fiscal year. The move is expected to ease a long-standing tax burden on drugmakers and align GST treatment more closely with business realities in the sector.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside AstraZeneca Pharma India:

Sanofi Consumer Healthcare India(1)Richa Chadha(1)Pfizer(1)New Delhi(1)Musafiri(1)Mumbai(1)